Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shire decides to fight FDA's proposed withdrawal of ProAmatine

This article was originally published in Scrip

Executive Summary

Plans by Shire to withdraw its hypotension drug, ProAmatine (alpha 1-agonist midodrine hydrochloride), have been put on hold as the company has revealed plans to appeal the US FDA's decision to seek withdrawal of the product. The company received a warning from the agency last month that inconclusive post-approval data threatened continued marketing authorisation.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts